Hero image

Research

We run to, not from, the world’s biggest health challenges.

The journey to discovery is guided by science – and inspired by patients

We use the power of leading-edge science to save and improve lives around the world. The path to discovery is often unclear, but we are tireless in seeking solutions for some of the world’s most difficult health challenges.

Our work in numbers

~19.2K

people employed in research and development

$13.5B

invested in R&D in 2022

We address the world’s most difficult health challenges, following leading-edge science

Hero_RGB_Discovery-Blue
Discovery & development

Step inside MSD Research Laboratories (MRL) where our quest to save and improve lives through research and development begins

B5 - Our pipeline__
Pipeline

We’re focused on inventing new medicines and vaccines to help more people

Father playing with young son at breakfast table

Our commitment to patients is unwavering

As long as there are still patients in hospitals, doctors and nurses desperate to add years to the lives of their patients, and a world where treatments aren’t accessible to all, we will be here, fighting with all we have to deliver more, sooner.

Discovery starts here

Our scientists are applying the latest groundbreaking research technologies and revolutionizing how we discover and develop medicines and vaccines

View our stories

In our commitment to R&D, the numbers speak for themselves

We follow the science where we can make the greatest difference

Read more

Next: In our commitment to R&D, the numbers speak for themselves

MSD’s Q4 and full-year 2022 earnings report

MSD’s Q4 and full-year 2022 results reflect sustained strong revenue growth. The company announced Q4 worldwide sales of $13.8 billion, an increase of 2% from Q4 2021. Full-year 2022 worldwide sales were $59.3 billion, an increase of 22% from full year 2021. “2022 was an exceptional year for MSD, which is a testament to the […]

Read more

Next: MSD’s Q4 and full-year 2022 earnings report

How antimicrobial resistance is threatening one of our most critical health tools

Why antibiotics are a critical medicine and how we can help protect them

Read more

Next: How antimicrobial resistance is threatening one of our most critical health tools

Celebrating the opening of our latest state-of-the-art facility

The FLEx Center will help us continue to harness the power of leading-edge science with agility

Read more

Next: Celebrating the opening of our latest state-of-the-art facility

MSD’s Q3 2022 earnings report

MSD’s Q3 2022 results reflect sustained strong business momentum across key growth drivers as well as investment and progress in the pipeline. The company announced Q3 worldwide sales of $15 billion, an increase of 14% from Q3 2021. “We continue to execute on our strategy, invest in leading-edge science and drive innovation as our colleagues deliver […]

Read more

Next: MSD’s Q3 2022 earnings report

In our commitment to R&D, the numbers speak for themselves

We follow the science where we can make the greatest difference

Read more

Next: In our commitment to R&D, the numbers speak for themselves

MSD’s Q4 and full-year 2022 earnings report

MSD’s Q4 and full-year 2022 results reflect sustained strong revenue growth. The company announced Q4 worldwide sales of $13.8 billion, an increase of 2% from Q4 2021. Full-year 2022 worldwide sales were $59.3 billion, an increase of 22% from full year 2021. “2022 was an exceptional year for MSD, which is a testament to the […]

Read more

Next: MSD’s Q4 and full-year 2022 earnings report

How antimicrobial resistance is threatening one of our most critical health tools

Why antibiotics are a critical medicine and how we can help protect them

Read more

Next: How antimicrobial resistance is threatening one of our most critical health tools

Celebrating the opening of our latest state-of-the-art facility

The FLEx Center will help us continue to harness the power of leading-edge science with agility

Read more

Next: Celebrating the opening of our latest state-of-the-art facility

MSD’s Q3 2022 earnings report

MSD’s Q3 2022 results reflect sustained strong business momentum across key growth drivers as well as investment and progress in the pipeline. The company announced Q3 worldwide sales of $15 billion, an increase of 14% from Q3 2021. “We continue to execute on our strategy, invest in leading-edge science and drive innovation as our colleagues deliver […]

Read more

Next: MSD’s Q3 2022 earnings report

Previous
Next
a cow standing against a blue sky

Protecting animal health

Our Animal Health business is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them.